Literature DB >> 11523566

EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy.

C F Boerkoel1, H Takashima, C A Bacino, D Daentl, J R Lupski.   

Abstract

Heterozygous mutations in the early growth response gene 2 (EGR2), which encodes a zinc-finger transcription factor that regulates the late stages of myelination, cause myelinopathies including congenital hypomyelinating neuropathy, Dejerine-Sottas neuropathy (DSN), and Charcot-Marie-Tooth disease type 1. We screened 170 unrelated neuropathy patients without mutations involving the peripheral myelin protein 22 gene (PMP22), the myelin protein zero gene (MPZ), or the gap junction protein beta1 gene (GJB1) and identified two DSN patients with the heterozygous mutation R359W in the alpha-helix domain of the first zinc-finger of EGR2. We now report that this mutation is a recurrent cause of DSN, and that expressivity ranges from that typical for DSN to a more rapidly progressive neuropathy that can cause death by age 6 years. Furthermore, in contrast to patients with typical DSN, patients with the EGR2 R359W mutation have more respiratory compromise and cranial nerve involvement.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523566     DOI: 10.1007/s100480100107

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  18 in total

Review 1.  Signals that determine Schwann cell identity.

Authors:  K R Jessen; R Mirsky
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

2.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

Review 3.  Molecular diagnostics of Charcot-Marie-Tooth disease and related peripheral neuropathies.

Authors:  Kinga Szigeti; Eva Nelis; James R Lupski
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 4.  Pluripotent stem cells for Schwann cell engineering.

Authors:  Ming-San Ma; Erik Boddeke; Sjef Copray
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

5.  Histopathology of the Inner Ear in Charcot-Marie-Tooth Syndrome Caused by a Missense Variant (p.Thr65Ala) in the MPZ Gene.

Authors:  Joseph B Nadol; E Tessa Hedley-Whyte; Sami Samir Amr; Jennifer T O Apos Malley; Takefumi Kamakura
Journal:  Audiol Neurootol       Date:  2019-01-24       Impact factor: 1.854

6.  Characteristics of demyelinating Charcot-Marie-Tooth disease with concurrent diabetes mellitus.

Authors:  Zhiliang Yu; Xiaohua Wu; Huijun Xie; Ying Han; Yangtai Guan; Yong Qin; Huimin Zheng; Jianming Jiang; Zhenmin Niu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

7.  EGR2 mutation enhances phenotype spectrum of Dejerine-Sottas syndrome.

Authors:  Elena Gargaun; Andreea Mihaela Seferian; Ruxandra Cardas; Anne-Gaelle Le Moing; Catherine Delanoe; Juliette Nectoux; Isabelle Nelson; Gisèle Bonne; Marie-Thérèse Bihoreau; Jean-François Deleuze; Anne Boland; Cécile Masson; Laurent Servais; Teresa Gidaro
Journal:  J Neurol       Date:  2016-05-09       Impact factor: 4.849

Review 8.  Autosomal-recessive forms of demyelinating Charcot-Marie-Tooth disease.

Authors:  O Dubourg; H Azzedine; C Verny; G Durosier; N Birouk; R Gouider; M Salih; A Bouhouche; A Thiam; D Grid; M Mayer; M Ruberg; M Tazir; A Brice; E LeGuern
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

9.  Functional, histopathologic and natural history study of neuropathy associated with EGR2 mutations.

Authors:  Kinga Szigeti; Wojciech Wiszniewski; Gulam Mustafa Saifi; Diane L Sherman; Norbert Sule; Adekunle M Adesina; Pedro Mancias; Sozos Ch Papasozomenos; Geoffrey Miller; Laura Keppen; Donna Daentl; Peter J Brophy; James R Lupski
Journal:  Neurogenetics       Date:  2007-08-24       Impact factor: 2.660

10.  Progesterone derivatives increase expression of Krox-20 and Sox-10 in rat Schwann cells.

Authors:  Valerio Magnaghi; Marinella Ballabio; Ilaria Roglio; Roberto C Melcangi
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.